Shanghai Henlius Partners with Sandoz for Global Commercialization of HLX13

An announcement from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.

Shanghai Henlius Biotech, Inc. has entered into a license agreement with Sandoz AG to commercialize its HLX13, a recombinant anti-CTLA-4 fully human monoclonal antibody injection, across the United States, 42 European countries, Japan, Australia, and Canada. This agreement includes significant financial terms, such as an upfront payment of $31 million, potential milestone payments totaling $160 million, and sales milestone payments up to $110 million, along with double-digit tiered royalties. The deal is expected to enhance Henlius’s market presence in the oncology sector, leveraging Sandoz’s commercialization capabilities in major global markets.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development of biosimilar and innovative biologic drugs. The company is involved in the pharmaceutical and healthcare industry, with a market focus on oncology treatments.

YTD Price Performance: 59.70%

Average Trading Volume: 1,619,282

Technical Sentiment Signal: Sell

Current Market Cap: HK$20.57B

For an in-depth examination of 2696 stock, go to TipRanks’ Stock Analysis page.